Index S&P 500
P/E 20.35
EPS (ttm) 9.42
Insider Own 1.90%
Shs Outstand 50.94M
Perf Week -1.42%
Market Cap 9.83B
Forward P/E 16.82
EPS next Y 11.40
Insider Trans -0.87%
Shs Float 50.30M
Perf Month -8.56%
Income 484.03M
PEG 4.20
EPS next Q 2.36
Inst Own 99.94%
Short Float / Ratio 3.38% / 3.66
Perf Quarter -7.37%
Sales 4.18B
P/S 2.35
EPS this Y -5.14%
Inst Trans 3.28%
Short Interest 1.70M
Perf Half Y -4.28%
Book/sh 63.43
P/B 3.02
EPS next Y 8.04%
ROA 6.33%
Target Price 244.31
Perf Year -2.60%
Cash/sh 4.05
P/C 47.34
EPS next 5Y 4.84%
ROE 16.41%
52W Range 181.22 - 262.00
Perf YTD -12.03%
Dividend -
P/FCF 33.96
EPS past 5Y 30.13%
ROI 7.64%
52W High -26.84%
Beta 1.33
Dividend % -
Quick Ratio 1.21
Sales past 5Y 16.52%
Gross Margin 33.63%
52W Low 5.77%
ATR 5.25
Employees 21400
Current Ratio 1.49
Sales Q/Q 8.92%
Oper. Margin 15.53%
RSI (14) 36.11
Volatility 1.92% 2.63%
Optionable Yes
Debt/Eq 0.95
EPS Q/Q -11.57%
Profit Margin 11.58%
Rel Volume 0.68
Prev Close 193.39
Shortable Yes
LT Debt/Eq 0.95
Earnings Aug 09 BMO
Payout 0.00%
Avg Volume 464.28K
Price 191.68
Recom 1.69
SMA20 -4.78%
SMA50 -6.29%
SMA200 -8.99%
Volume 317,735
Change -0.88%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-13-23 Initiated
TD Cowen
Market Perform
$212
Jul-10-23 Downgrade
Citigroup
Buy → Neutral
$260 → $225
Feb-23-23 Upgrade
Guggenheim
Neutral → Buy
$255
Jan-12-23 Downgrade
Jefferies
Buy → Hold
Sep-30-22 Upgrade
Jefferies
Hold → Buy
$240
Aug-25-22 Initiated
Credit Suisse
Outperform
$285
Aug-04-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$350 → $250
May-24-22 Initiated
Guggenheim
Neutral
Apr-25-22 Downgrade
Jefferies
Buy → Hold
$370 → $280
Apr-07-22 Initiated
Stephens
Overweight
$377
Feb-17-22 Upgrade
Citigroup
Neutral → Buy
$400
Feb-17-22 Reiterated
UBS
Buy
$465 → $420
Feb-17-22 Reiterated
Morgan Stanley
Overweight
$465 → $430
Feb-17-22 Reiterated
Deutsche Bank
Buy
$409 → $350
Feb-17-22 Reiterated
BofA Securities
Buy
$445 → $400
Aug-05-21 Resumed
Credit Suisse
Neutral
$385
Dec-16-20 Downgrade
Citigroup
Buy → Neutral
$270 → $250
Sep-10-20 Upgrade
Jefferies
Hold → Buy
$254
Jul-01-20 Upgrade
BofA Securities
Neutral → Buy
$192
May-13-20 Upgrade
UBS
Neutral → Buy
$177 → $200
Show Previous Ratings
Oct-02-23 11:35AM
Sep-27-23 12:04PM
Sep-26-23 08:02AM
08:00AM
Sep-25-23 11:40AM
08:00AM
Loading…
08:00AM
Sep-21-23 11:36AM
Sep-20-23 08:30AM
Sep-18-23 12:03PM
Sep-15-23 08:36AM
Sep-14-23 08:00AM
Sep-12-23 11:33AM
Sep-11-23 08:00AM
Sep-08-23 11:30AM
Sep-06-23 03:02PM
10:35AM
Loading…
10:35AM
08:00AM
Aug-30-23 07:32PM
05:40PM
(American City Business Journals)
Aug-24-23 06:24PM
08:00AM
Aug-10-23 01:42PM
Aug-09-23 02:50PM
12:33PM
12:13PM
11:12AM
09:30AM
08:29AM
08:15AM
07:10AM
07:00AM
Loading…
07:00AM
Aug-04-23 04:04PM
03:32PM
Aug-03-23 06:05PM
Aug-02-23 11:31AM
Aug-01-23 08:00AM
Jul-31-23 11:30AM
Jul-21-23 01:40PM
01:25PM
Jul-20-23 12:54PM
Jul-19-23 08:00AM
Jul-17-23 10:27AM
Jul-04-23 07:32AM
Jun-14-23 11:21AM
08:50AM
07:24AM
Jun-13-23 09:45AM
04:30AM
Jun-12-23 08:00AM
Jun-09-23 08:53AM
Jun-08-23 04:30PM
Jun-05-23 08:00AM
Jun-01-23 11:17AM
May-31-23 11:35AM
08:00AM
May-17-23 10:35AM
May-14-23 04:05PM
10:28AM
May-12-23 01:31AM
(Thomson Reuters StreetEvents)
May-11-23 08:04PM
(Morningstar Research) +5.07%
12:25PM
11:42AM
09:39AM
09:30AM
08:15AM
07:00AM
May-01-23 11:14AM
08:00AM
Apr-24-23 06:21PM
Apr-12-23 12:33PM
12:33PM
Apr-11-23 08:30AM
Apr-10-23 08:00AM
Apr-09-23 08:59AM
Mar-31-23 08:02AM
Mar-24-23 11:30AM
Mar-16-23 07:30AM
Mar-15-23 03:14PM
Mar-14-23 08:28AM
Mar-13-23 08:00AM
08:00AM
Mar-09-23 08:00AM
Mar-03-23 04:59PM
(The Wall Street Journal)
Mar-02-23 05:18AM
Feb-27-23 07:56AM
06:50AM
Feb-23-23 07:25PM
04:33PM
05:17AM
Feb-22-23 07:22PM
(Morningstar Research) -10.06%
04:18PM
04:03PM
(Investor's Business Daily)
02:47PM
02:34PM
01:57PM
01:19PM
11:55AM
09:38AM
(Investor's Business Daily)
08:40AM
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment consists of the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and the management of the clients? research operations. The Discovery and Safety Assessment segment offers integrated drug discovery services directed at the identification, screening, and selection of a lead compound for drug development and offers safety assessment services, including bioanalysis, drug metabolism, pharmacokinetics, toxicology, and pathology. The Manufacturing Support segment consists of Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services, Biologics Solutions, which performs specialized testing of biologics as well as contract development and manufacturing, and Avian Vaccine Services, which supplies specific-pathogen-free chicken eggs and chickens. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
WALLMAN RICHARD F Director Aug 24 Buy 198.79 1,000 198,786 1,000 Aug 29 04:23 PM Barbo William D Corporate Executive VP & CCO Aug 10 Option Exercise 144.67 5,511 797,276 9,103 Aug 14 04:17 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Aug 10 Option Exercise 144.67 1,471 212,810 11,411 Aug 14 04:15 PM Barbo William D Corporate Executive VP & CCO Aug 10 Sale 217.24 5,763 1,251,954 3,592 Aug 14 04:17 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Aug 10 Sale 216.54 1,471 318,530 9,940 Aug 14 04:15 PM LaPlume Joseph W EVP, Corp Strategy & Develop Aug 10 Sale 216.52 700 151,564 24,983 Aug 14 04:11 PM LaPlume Joseph W EVP, Corp Strategy & Develop May 15 Sale 190.39 345 65,685 24,026 May 16 02:18 PM LaPlume Joseph W EVP, Corp Strategy & Develop May 12 Sale 193.03 959 185,116 24,371 May 15 02:49 PM MASSARO GEORGE Director May 11 Sale 193.43 288 55,708 4,964 May 15 02:42 PM WALLMAN RICHARD F Director Feb 23 Buy 220.73 1,750 386,278 21,864 Feb 24 04:20 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 16 Option Exercise 109.34 4,558 498,372 10,568 Feb 21 05:39 PM Girshick Birgit Corporate Executive VP & COO Feb 16 Option Exercise 109.34 3,205 350,435 44,243 Feb 17 05:29 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 16 Sale 254.41 4,558 1,159,619 6,010 Feb 21 05:39 PM Girshick Birgit Corporate Executive VP & COO Feb 16 Sale 254.39 3,205 815,310 41,038 Feb 17 05:29 PM FOSTER JAMES C Chairman, President and CEO Feb 15 Sale 250.00 20,000 5,000,017 216,594 Feb 17 04:02 PM Barbo William D Corporate Executive VP & CCO Dec 02 Option Exercise 109.34 3,205 350,435 7,008 Dec 06 04:40 PM WALLMAN RICHARD F Director Dec 02 Buy 218.90 1,500 328,350 20,114 Dec 06 04:12 PM Barbo William D Corporate Executive VP & CCO Dec 02 Sale 219.91 3,205 704,814 3,803 Dec 06 04:40 PM LaPlume Joseph W EVP, Corp Strategy & Develop Dec 01 Option Exercise 109.34 6,409 700,760 26,641 Dec 05 04:55 PM LaPlume Joseph W EVP, Corp Strategy & Develop Dec 01 Sale 224.25 6,409 1,437,205 20,232 Dec 05 04:55 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Nov 16 Option Exercise 109.34 855 93,486 7,293 Nov 17 05:27 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Nov 16 Sale 248.59 855 212,544 6,438 Nov 17 05:27 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Nov 15 Option Exercise 109.34 2,279 249,186 4,778 Nov 17 05:22 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Nov 15 Sale 249.90 2,279 569,522 2,499 Nov 17 05:22 PM LaPlume Joseph W EVP, Corp Strategy & Develop Nov 04 Sale 216.36 534 115,536 20,232 Nov 07 06:54 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite